Russell Investments Group
ELTX icon

Russell Investments Group’s Elicio Therapeutics ELTX Stock Holding History

Russell Investments Group’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.04K Buy
+1,033
New +$10.4K ﹤0.01% 4064
2022
Q1 		– Sell
-24,809
Closed -$718K – 2800
2021
Q4 		$718K Hold
24,809
– – ﹤0.01% 2308
2021
Q3 		$2.42M Buy
+24,809
New +$2.68M ﹤0.01% 1719

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Russell Investments Group's ELTX Position: Q2 2026 in Review

Russell Investments Group opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 1,033 shares worth $4.04K. The stake represents ﹤0.01% of the portfolio and ranks #4064 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in ELTX as recently as Q4 2021.

Russell Investments Group first reported a position in ELTX in Q3 2021 and has held it in 3 quarters since. The position peaked at $2.42M in Q3 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Russell Investments Group held 1,033 shares of Elicio Therapeutics worth $4.04K as of Q2 2026.
  • Elicio Therapeutics was a new Russell Investments Group position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #4064 holding.
  • Russell Investments Group first reported a position in Elicio Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Russell Investments Group's Elicio Therapeutics position peaked at $2.42M in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.